Citations

Showing 10 of 107941 citations.

IGF-I Activation of the AKT Pathway Is Impaired in Visceral But Not Subcutaneous Preadipocytes from Obese Subjects
Cleveland-Donovan, Kelly, Maile, Laura A. , Tsiaras, William G. , Tchkonia, Tamar , Kirkland, James L. , Boney, Charlotte M. , Tchkonia, T

Mayo Clinic

Endocrinology | June 17, 2010 | Volume: 151 | Issue: 8 | Pages: 3752-3763

10.1210/en.2010-0043 | PMID 20555032 Get It

The Structure of the TNFRSF13C Promoter Enables Differential Expression of BAFF-R during B Cell Ontogeny and Terminal Differentiation
Mihalcik, Stephen A. , Huddleston, P.M. , Wu, Xiaosheng , Jelinek, Diane F., Huddleston, Paul M

Mayo Clinic

The Journal of Immunology | June 17, 2010 | Volume: 185 | Issue: 2 | Pages: 1045-1054

10.4049/jimmunol.1001120 | PMID 20554963 Get It

Abstract The B cell-activating factor of the TNF family receptor (BAFF-R), encoded by the TNFRSF13C gene, is critically important for transitional B cell survival to maturity. Thus, ligation of BAFF-R by BAFF delivers a potent survival signal. Reports implicating the BAFF/BAFF-R signaling axis in the pathogenesis of autoimmune human diseases and B lineage malignancies have largely prompted studies focusing on BAFF expression; however, there is an equally critical need to better understand BAFF-R expression. Initial BAFF-R expression, although characterized in murine B cells, has not yet been reported in human B lymphopoiesis. In this study, we first demonstrate that BAFF-R expression is absent from early precursors and is acquired by bone marrow B cells newly expressing the BCR. We next focused on identifying the specific genomic region that controls BAFF-R expression in mature B cells (i.e., the TNFRSF13C promoter). To accomplish this, we used in silico tools examining interspecies genomic conservation in conjunction with reporter constructs transfected into malignant B and plasma cell lines. DNase protection assays using nuclear extracts from BAFF-R–expressing cells suggested potential regulatory sites, which allowed the generation of EMSA probes that bound NFs specific to BAFF-R–expressing cells. With a more stringent analysis of interspecies homology, these assays identified a site at which a single nucleotide substitution could distinctly impact promoter activity. Finally, chromatin immunoprecipitation assays revealed the in vivo binding of the specific transcription factor c-Rel to the most proximal genomic region, and c-Rel small interfering RNA transfections in BAFF-R–expressing lines demonstrated a coincident knockdown of both c-Rel and BAFF-R mRNA.
Glucose Meter Performance Criteria for Tight Glycemic Control Estimated by Simulation Modeling
Karon, Brad S. , Boyd, James C. , Klee, George G.

Mayo Clinic

Clinical Chemistry | June 16, 2010 | Volume: 56 | Issue: 7 | Pages: 1091-1097

10.1373/clinchem.2010.145367 | PMID 20511447 Get It

AbstractBackground: Glucose meter analytical performance criteria required for safe and effective management of patients on tight glycemic control (TGC) are not currently defined. We used simulation modeling to relate glucose meter performance characteristics to insulin dosing errors during TGC.Methods: We used 29 920 glucose values from patients on TGC at 1 institution to represent the expected distribution of glucose values during TGC, and we used 2 different simulation models to relate glucose meter analytical performance to insulin dosing error using these 29 920 initial glucose values and assuming 10%, 15%, or 20% total allowable error (TEa) criteria.Results: One-category insulin dosing errors were common under all error conditions. Two-category insulin dosing errors occurred more frequently when either 20% or 15% TEa was assumed compared with 10% total error. Dosing errors of 3 or more categories, those most likely to result in hypoglycemia and thus patient harm, occurred infrequently under all error conditions with the exception of 20% TEa.Conclusions: Glucose meter technologies that operate within a 15% total allowable error tolerance are unlikely to produce large (≥3-category) insulin dosing errors during TGC. Increasing performance to 10% TEa should reduce the frequency of 2-category insulin dosing errors, although additional studies are necessary to determine the clinical impact of such errors during TGC. Current criteria that allow 20% total allowable error in glucose meters may not be optimal for patient management during TGC.
Endothelial Function as a Functional Expression of Cardiovascular Risk Factors
Reriani, Martin, Lerman, Lilach O. , Lerman, Amir

Mayo Clinic

Biomarkers in Medicine | June 16, 2010 | Volume: 4 | Issue: 3 | Pages: 351-360

10.2217/bmm.10.61 | PMID 20550469 Get It

A Method for Measuring Wave Speed Dispersion in Arteries by Resonance
Zhang, Xiaoming , Greenleaf, James F., Zhang, Xiaoming

Mayo Clinic

Volume 2: Biomedical and Biotechnology Engineering | June 15, 2010 | Volume: No volume available | Issue: No issue available | Pages: 453-455

10.1115/imece2009-10508 Get It

Cardiovascular disease (CVD) has been the number one killer in the United States. It has long been recognized that a high percentage of all cardiovascular disease is associated with the hardening of arteries or arteriosclerosis. Several imaging techniques, including x-ray angiography, ultrasound, magnetic resonance imaging (MRI), etc., are available for imaging atherosclerotic arteries. Most imaging techniques measure luminal diameter, wall thickness and plaque volume. However, no current imaging methods can measure elasticity of the arterial wall. Pulse wave velocity (PWV) is a simple and robust method to measure arterial stiffness. However, PWV can not evaluate the local arterial stiffness. We have developed a novel ultrasound method for estimating local elasticity of arteries by the wave speed dispersion. In this paper, we present a method to measure the wave speed dispersion by resonance. Theory was developed to calculate the wave speed in cylindrical tubes. Experiments were done on a rubber tube. The resonance of the tube was generated by an air-coupled ultrasound transducer. The resonance frequency was measured by a laser vibrometer. Theoretical and experimental wave dispersions were compared. This method may be useful in characterizing the elastic properties of arterial samples where the wave speed dispersion can not be easily measured.
Confirmation of Linkage to and Localization of Familial Colon Cancer Risk Haplotype on Chromosome 9q22
Gray‐McGuire, Courtney, Guda, Kishore , Adrianto, Indra , Lin, Chee Paul , Natale, Leanna, Potter, John D. , Lindor, Noralane M. , Goode, Ellen L. , Jenkins, Robert B. , Jenkins, Mark A. , Young, Joanne , Buchanan, Daniel D. , Gallinger, Steve, Lewis, Susan, Elston, Robert C. , Markowitz, Sanford D. , Wiesner, Georgia L. , Newcomb, Polly A. , Poole, Elizabeth M. , Ulrich, Cornelia M. , Fridley, Brooke L. , Marchand, Loı̈c Le , Casey, Graham , Haile, Robert W. , Hopper, John L. , Adams, Mark , Lewis, Susan, Willis, Joseph , Buchanan, Daniel D , Jenkins, Mark A , Potter, John D

Mayo Clinic

Cancer Research | June 15, 2010 | Volume: 70 | Issue: 13 | Pages: 5409-5418

10.1158/0008-5472.can-10-0188 | PMID 20551049 Get It

Abstract Genetic risk factors are important contributors to the development of colorectal cancer. Following the definition of a linkage signal at 9q22-31, we fine mapped this region in an independent collection of colon cancer families. We used a custom array of single-nucleotide polymorphisms (SNP) densely spaced across the candidate region, performing both single-SNP and moving-window association analyses to identify a colon neoplasia risk haplotype. Through this approach, we isolated the association effect to a five-SNP haplotype centered at 98.15 Mb on chromosome 9q. This haplotype is in strong linkage disequilibrium with the haplotype block containing HABP4 and may be a surrogate for the effect of this CD30 Ki-1 antigen. It is also in close proximity to GALNT12, also recently shown to be altered in colon tumors. We used a predictive modeling algorithm to show the contribution of this risk haplotype and surrounding candidate genes in distinguishing between colon cancer cases and healthy controls. The ability to replicate this finding, the strength of the haplotype association (odds ratio, 3.68), and the accuracy of our prediction model (∼60%) all strongly support the presence of a locus for familial colon cancer on chromosome 9q. Cancer Res; 70(13); 5409–18. ©2010 AACR.
USE OF AUTOGENOUS VEIN OR SYNTHETIC GRAFTS
Hakaim, Albert G., Oldenburg, W. Andrew

Mayo Clinic

Dialysis Access | June 15, 2010 | Volume: No volume available | Issue: No issue available | Pages: 181-210

10.1142/9781848161726_0009 Get It

Reply to T.A. James et al
Boughey, Judy C. , Goetz, Matthew P. , Degnim, Amy C.

Mayo Clinic

Journal of Clinical Oncology | June 15, 2010 | Volume: 28 | Issue: 21 | Pages: e365-e365

10.1200/jco.2010.28.3309 Get It

Successful Nonsurgical Treatment of Pneumomediastinum, Pneumothorax, Pneumoperitoneum, Pneumoretroperitoneum, and Subcutaneous Emphysema following ERCP
Fujii, Larissa L., Lau, A. , Fleischer, David E., Harrison, M. Edwyn

Mayo Clinic

Gastroenterology Research and Practice | June 14, 2010 | Volume: 2010 | Issue: No issue available | Pages: 1-7

10.1155/2010/289135 | PMID 20631834 Get It

Complications related to endoscopic retrograde cholangiopancreatography (ERCP) include pancreatitis, hemorrhage, cholangitis, and perforation. ERCP-related perforation is uncommon, but mortality rates are high. Diagnosis requires a high clinical suspicion for early detection to allow optimal management of the perforation and a better prognosis. Treatment depends on the location and mechanism and increasingly involves nonoperative management. We report a case of successful nonsurgical treatment of a patient with extensive air involving the peritoneum, retroperitoneum, thorax, mediastinum, and subcutaneous tissues following an ERCP perforation.